Thelansis

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection with a high mortality rate. The incidence of IPA is rising due to an increase in the number of patients undergoing transplants and receiving chemotherapy and immunosuppressive therapy. Diagnosis is challenging due to the non-specific nature of symptoms. Voriconazole is the mainstay of treatment. IPA usually occurs in severely immunocompromised patients. Classic at-risk patients with prolonged neutropenia, either due to chemotherapy or immunosuppressive therapy, post hematopoietic stem cell transplant (SCT), or solid organ transplant. ·        The mortality rate of IPA continues to be very high, exceeding 50% in neutropenic patients and 90% in SCT recipients. The competitive landscape of Invasive pulmonary aspergillosis (IPA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with a...